Home › Companies › Xeris Biopharma Holdings, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Xeris Biopharma Holdings, Inc.’s Form 8-K, filed June 5, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2026: 4 items on Xeris Biopharma Holdings, Inc.’s Form 8-K, filed June 5, 2026: 2 elected · 2 approved.
Significant dissent: 2 directors (39.8%, 28.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Xeris Biopharma Holdings, Inc. in the interactive database Compare manager voting policies
These tallies are Xeris Biopharma Holdings, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dawn Halkuff | 62,581,577 | -- | -- | 24,906,166 | 40,780,330 | 72% | Elected | — |
| Elect Director: John Johnson | 52,665,077 | -- | -- | 34,822,666 | 40,780,330 | 60% | Elected | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm | 125,789,818 | 1,032,530 | 1,445,725 | -- | -- | 99.2% | Approved | — |
| 3. Advisory Vote to Approve Named Executive Officer Compensation | 82,230,204 | 4,658,035 | 599,504 | -- | 40,780,330 | 95% | Approved | — |
Source: Xeris Biopharma Holdings, Inc., Form 8-K, filed with the SEC on June 5, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
228 asset managers disclosed a vote on at least one Xeris Biopharma Holdings, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
72% Majority: yes · of votes cast
Description as filed by funds: To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Dawn Halkuff
Xeris Biopharma Holdings, Inc.’s own tally for this item (“Elect Director: Dawn Halkuff”): 62,581,577 for, 24,906,166 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each nominee was elected by a plurality vote in accordance with the Company's Amended and Restated Bylaws, as follows:”
Support: 72% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 26,424,881 for, 3,848,885 withheld, 114 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,573,015 | 0 | 114 | 69,700 | For |
| BlackRock | 6,040,444 | 0 | 0 | 0 | For |
| Fidelity | 3,474,721 | 0 | 0 | 67,400 | For |
| TIAA | 3,311,894 | 0 | 0 | 0 | For |
| Charles Schwab | 1,463,769 | 0 | 0 | 0 | For |
| State Street | 1,248 | 0 | 0 | 1,096,961 | Withhold |
| Federated Hermes | 490,423 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 431,010 | Withhold |
| Voya | 0 | 0 | 0 | 399,614 | Withhold |
| Bridge Builder Trust | 372,451 | 0 | 0 | 0 | For |
| Royce | 356,000 | 0 | 0 | 0 | For |
| Equitable | 252,494 | 0 | 0 | 90,380 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 251,634 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 245,592 | Withhold |
| Janus Detroit Street Trust | 0 | 0 | 0 | 211,520 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 207,543 | Withhold |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 199,971 | Withhold |
| 1290 Funds | 0 | 0 | 0 | 173,590 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 169,954 | Withhold |
| TIFF INVESTMENT PROGRAM | 120,395 | 0 | 0 | 0 | For |
| Goldman Sachs | 113,479 | 0 | 0 | 0 | For |
| Northern Trust | 95,602 | 0 | 0 | 0 | For |
| SEI | 93,145 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 84,073 | Withhold |
| Global X | 74,612 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
60% Majority: yes · of votes cast
Description as filed by funds: To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John Johnson
Xeris Biopharma Holdings, Inc.’s own tally for this item (“Elect Director: John Johnson”): 52,665,077 for, 34,822,666 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each nominee was elected by a plurality vote in accordance with the Company's Amended and Restated Bylaws, as follows:”
Support: 60% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 18,447,196 for, 11,826,522 withheld, 162 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,565,464 | 0 | 162 | 77,202 | For |
| BlackRock | 0 | 0 | 0 | 6,040,444 | Withhold |
| Fidelity | 2,903,405 | 0 | 0 | 638,716 | Mixed |
| TIAA | 3,311,894 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,463,769 | Withhold |
| State Street | 1,096,920 | 0 | 0 | 1,289 | For |
| Federated Hermes | 490,423 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 431,010 | Withhold |
| Voya | 0 | 0 | 0 | 399,614 | Withhold |
| Bridge Builder Trust | 342,700 | 0 | 0 | 29,751 | Mixed |
| Royce | 356,000 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 342,874 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 251,634 | Withhold |
| Victory Capital | 0 | 0 | 0 | 245,592 | Withhold |
| Janus Detroit Street Trust | 0 | 0 | 0 | 211,520 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 207,543 | Withhold |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 199,971 | Withhold |
| 1290 Funds | 0 | 0 | 0 | 173,590 | Withhold |
| Lincoln Financial | 105,200 | 0 | 0 | 64,754 | Mixed |
| TIFF INVESTMENT PROGRAM | 0 | 0 | 0 | 120,395 | Withhold |
| Goldman Sachs | 113,479 | 0 | 0 | 0 | For |
| Northern Trust | 95,602 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 0 | 93,145 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 84,073 | Withhold |
| Global X | 0 | 0 | 0 | 74,612 | Withhold |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
95% Approved · of votes cast
Prior year: 92.8% for (June 4, 2025 meeting) ▲ 1.9 pts
Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
Xeris Biopharma Holdings, Inc.’s own tally for this item (“3. Advisory Vote to Approve Named Executive Officer Compensation”): 82,230,204 for, 4,658,035 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Three: Advisory Vote to Approve Named Executive Officer Compensation The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Sec…”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,642,806 | 20 | 3 | 0 | For |
| BlackRock | 6,040,444 | 0 | 0 | 0 | For |
| Fidelity | 3,542,121 | 0 | 0 | 0 | For |
| TIAA | 3,311,894 | 0 | 0 | 0 | For |
| Charles Schwab | 1,463,769 | 0 | 0 | 0 | For |
| State Street | 1,098,178 | 31 | 0 | 0 | For |
| Federated Hermes | 490,423 | 0 | 0 | 0 | For |
| First Trust | 431,010 | 0 | 0 | 0 | For |
| Voya | 399,614 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 372,451 | 0 | 0 | 0 | For |
| Royce | 356,000 | 0 | 0 | 0 | For |
| Equitable | 342,874 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 251,634 | 0 | 0 | 0 | For |
| Victory Capital | 245,592 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 211,520 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 207,543 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 199,971 | 0 | 0 | 0 | For |
| 1290 Funds | 173,590 | 0 | 0 | 0 | For |
| Lincoln Financial | 169,954 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 120,395 | 0 | 0 | 0 | For |
| Goldman Sachs | 113,479 | 0 | 0 | 0 | For |
| Northern Trust | 95,602 | 0 | 0 | 0 | For |
| SEI | 93,145 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 84,073 | 0 | 0 | 0 | For |
| Global X | 74,612 | 0 | 0 | 0 | For |
Fund voting reports, all 60 managers: 30,298,882 for, 22,408 against, 3 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 5,738,763 | 44,680 | 0 | 0 | For |
| State Street | 4,470,966 | 10,833 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,483,286 | 0 | 0 | 0 | For |
| Nuveen | 3,388,130 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 0 | 1,891,584 | 0 | 0 | Against |
| Wellington | 1,484,996 | 0 | 0 | 0 | For |
| Charles Schwab | 1,464,047 | 0 | 0 | 0 | For |
| Vanguard | 1,371,081 | 0 | 0 | 0 | For |
| Northern Trust | 1,249,690 | 14,723 | 0 | 0 | For |
| Two Sigma | 1,263,856 | 0 | 0 | 0 | For |
| DE Shaw | 1,192,476 | 0 | 0 | 0 | For |
| Voss Capital, LP | 1,110,244 | 0 | 0 | 0 | For |
| Knott David M Jr | 1,060,000 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 844,736 | 114,325 | 0 | 0 | Mixed |
| Goldman Sachs | 911,169 | 0 | 0 | 0 | For |
| Federated Hermes | 847,939 | 0 | 0 | 0 | For |
| Granahan Investment Management, LLC | 771,761 | 0 | 0 | 0 | For |
| AQR | 733,517 | 0 | 0 | 0 | For |
| ALGERT GLOBAL LLC | 609,692 | 0 | 0 | 0 | For |
| UBS | 0 | 581,790 | 0 | 0 | Against |
| Voya | 558,910 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 540,213 | 0 | 0 | Against |
| Fidelity | 511,313 | 0 | 0 | 0 | For |
| Roundview Capital LLC | 491,244 | 0 | 0 | 0 | For |
| T. Rowe Price | 477,454 | 0 | 0 | 0 | For |
Institutional-manager reports, all 184 managers: 40,159,113 for, 3,508,669 against, 12,251 abstained, 20,026 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.2% Approved · of votes cast
Prior year: 99.3% for (June 4, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Xeris Biopharma Holdings, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 125,789,818 for, 1,032,530 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 62 asset managers below reported 30,322,328 for, 3 against, 2 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,642,824 | 3 | 2 | 0 | For |
| BlackRock | 6,040,444 | 0 | 0 | 0 | For |
| Fidelity | 3,542,121 | 0 | 0 | 0 | For |
| TIAA | 3,311,894 | 0 | 0 | 0 | For |
| Charles Schwab | 1,463,769 | 0 | 0 | 0 | For |
| State Street | 1,098,209 | 0 | 0 | 0 | For |
| Federated Hermes | 490,423 | 0 | 0 | 0 | For |
| First Trust | 431,010 | 0 | 0 | 0 | For |
| Voya | 399,614 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 372,451 | 0 | 0 | 0 | For |
| Royce | 356,000 | 0 | 0 | 0 | For |
| Equitable | 342,874 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 251,634 | 0 | 0 | 0 | For |
| Victory Capital | 245,592 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 211,520 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 207,543 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 199,971 | 0 | 0 | 0 | For |
| 1290 Funds | 173,590 | 0 | 0 | 0 | For |
| Lincoln Financial | 169,954 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 120,395 | 0 | 0 | 0 | For |
| Goldman Sachs | 113,479 | 0 | 0 | 0 | For |
| Northern Trust | 95,602 | 0 | 0 | 0 | For |
| SEI | 93,145 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 84,073 | 0 | 0 | 0 | For |
| Global X | 74,612 | 0 | 0 | 0 | For |
Showing the 25 largest of 62 asset managers. All 62 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 172,558,783 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.59% |
| 2 | BlackRock | 3.50% |
| 3 | Fidelity | 2.05% |
| 4 | TIAA | 1.92% |
| 5 | Charles Schwab | 0.85% |
| 6 | State Street | 0.64% |
| 7 | Federated Hermes | 0.28% |
| 8 | First Trust | 0.25% |
| 9 | Voya | 0.23% |
| 10 | Bridge Builder Trust | 0.22% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 3.35% |
| 2 | State Street | 2.60% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 2.02% |
| 4 | Nuveen | 1.96% |
| 5 | Legal & General Investment Management Ltd | 1.10% |
| 6 | Wellington | 0.86% |
| 7 | Charles Schwab | 0.85% |
| 8 | Vanguard | 0.79% |
| 9 | Northern Trust | 0.73% |
| 10 | Two Sigma | 0.73% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 12,945,785 | 7.50% | Form 13F, quarter ended March 31, 2026 |
| D.E. Shaw | 7,788,811 | 4.51% | Form 13F, quarter ended March 31, 2026 |
| State Street | 4,658,174 | 2.70% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 2,707,783 | 1.57% | Form 13F, quarter ended March 31, 2026 |
| Wellington Management | 2,171,354 | 1.26% | Form 13F, quarter ended March 31, 2026 |
| Two Sigma | 1,924,202 | 1.12% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 1,613,650 | 0.94% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 172,558,783 shares outstanding, as reported by Xeris Biopharma Holdings, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Xeris Biopharma Holdings, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 228 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 949 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — Xeris Biopharma Holdings, Inc.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Xeris Biopharma Holdings, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Xeris Biopharma Holdings, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Xeris Biopharma Holdings, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Xeris Biopharma Holdings (XERS) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/xeris-biopharma-holdings-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.